title: Economics of stratified medicine in rheumatoid arthritis.
abstract: Clinically relevant examples of stratified medicine are available for patients with rheumatoid arthritis (RA). The aim of this study was to understand the current economic evidence for stratified medicine in RA. Two systematic reviews were conducted to identify: (1) all economic evaluations of stratified treatments for rheumatoid arthritis, or those which have used a subgroup analysis, and (2) all stated preference studies of treatments for rheumatoid arthritis. Ten economic evaluations of stratified treatments for RA, 38 economic evaluations including with a subgroup analysis and eight stated preference studies were identified. There was some evidence to support that stratified approaches to treating a patient with RA may be cost-effective. However, there remain key gaps in the economic evidence base needed to support the introduction of stratified medicine in RA into healthcare systems and considerable uncertainty about how proposed stratified approaches will impact future patient preferences, outcomes and costs when used in routine practice.
authors.affiliation: Manchester Centre for Health Economics, Institute of Population Health, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK.
authors.forename: Sean
authors.initials: S
authors.lastname: Gavan
authors.forename: Mark
authors.initials: M
authors.lastname: Harrison
authors.forename: Cynthia
authors.initials: C
authors.lastname: Iglesias
authors.forename: Anne
authors.initials: A
authors.lastname: Barton
authors.forename: Andrea
authors.initials: A
authors.lastname: Manca
authors.forename: Katherine
authors.initials: K
authors.lastname: Payne
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans
chemical_list: D018501:Antirheumatic Agents